Endocrine pharmacology of antiestrogens as antitumor agents

Endocrine Reviews

Volumn 11, Issue 4, 1990, Pages 578-610

  Jordan, V Craig ^a   Murphy, Catherine S ^a,b  

^a UNIVERSITY OF WISCONSIN   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; DROLOXIFENE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; RALOXIFENE; TAMOXIFEN; TOREMIFENE; TRIOXIFENE; ZINDOXIFENE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; BREAST CANCER; CANCER CHEMOTHERAPY; CATARACT; CONTROLLED STUDY; DRUG RESISTANCE; LIVER CANCER; LIVER TOXICITY; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; OSTEOPOROSIS; OVULATION INDUCTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TERATOGENICITY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMAN; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

EID: 0025242415     PISSN: 0163769X     EISSN: 0163769X     Source Type: Journal    
DOI: 10.1210/edrv-11-4-578     Document Type: Article

References (453)

1. Lerner LJ, Holthaus Jr FJ, Thompson CR 1958 A nonsteroidal estrogen antagonist l-(p-2-diethylaminoethoxyphenyl)-l-phenyl-2-p-methoxyphenylethanol. Endocrinology 63:295
2. Lerner LJ 1981 The first non-steroidal antioestrogen-MER-25. In: Sutherland RL, Jordan VC (eds) Nonsteroidal Antioestrogens: Molecular Pharmacology and Antitumour Activity. Academic Press, Sydney, Australia, p 1
3. Lerner LJ, Jordan VC 1990 Development of antiestrogens and their use in breast cancer: eighth Cain Memorial Award Lecture. Cancer Res 50:4177
4. Holtkamp DE, Greslin JG, Root CA, Lerner LJ 1960 Gonadotrophin inhibiting and antifecundity effects of chloramiphene. Proc Soc Exp Biol Med 105:197
5. Greenblatt RB, Barfield WE, Jungck EC, Ray AW 1961 Induction of ovulation with MRL-41. Preliminary report. JAMA 178:101
6. Huppert LC 1979 Induction of ovulation with clomiphene citrate. Fertil Steril 31:1
7. Emmens CW 1970 Postcoital contraception. Br Med Bull 26:45
8. Lunan CB, Klopper A 1975 Antioestrogens: a review. Clin Endocrinol 4:551.
9. Boyd S 1900 On oophorectomy in cancer of the breast. Br Med J ii:1161
10. Haddow A, Watkinson JM, Paterson E 1944 Influence of synthetic oestrogens upon advanced malignant disease. Br Med J ii:393
11. Walpole AL, Paterson E 1949 Synthetic oestrogens in mammary cancer. Lancet 2:783
12. Jensen EV, Block GE, Smith S, Kyser K, DeSombre ER 1971 Estrogen receptors and breast cancer response to adrenalectomy. In: Hall TC (ed) Prediction of response in cancer therapy. Natl Cancer Inst Monogr 34:55
13. McGuire WL, Carbone PP, Vollmer EP (eds) 1975 Estrogen Receptors in Human Breast Cancer. Raven Press, New York
14. Jensen EV, Jacobson HI, Smith S, Jungblut PW, DeSombre ER 1972 The use of estrogen and antagonists in hormone receptor studies. Gynecol Invest 3:108
15. Skidmore JR, Walpole AL, Woodburn J 1972 Effect of some triphenylethylenes on oestradiol binding in vitro to macromolecules from uterus and anterior pituitary. J Endocrinol 52:289
16. Legha SS, Carter SK 1976 Antiestrogens in the treatment of breast cancer. Cancer Treat Rev 3:205
17. Cole MP, Jones CTA, Todd IDH 1971 A new antioestrogenic agent in late breast cancer. An early clinical appraisal of ICI46.474. Br J Cancer 25:270
18. Ward HWC 1973 Antioestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J i:13
19. O’Halloran MJ, Maddock PG 1974 ICI46.474 in breast cancer. J Irish Med Assoc 67:38
20. Proceedings of the Annual Spring Meeting of the Primary Breast Cancer Therapy Group: Tamoxifen workshop. (Key Biscayne, Florida, April 28, 1976). Cancer Treat Rep 60:1409
21. Jordan VC 1988 Development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole. Breast Cancer Res Treat 11:197
22. Buchanan RB, Blarney RW, Durrent KR, Howell A, Paterson AG, Preece PE, Smith DC, Williams CJ, Wilson RG 1986 A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 4:1326
23. Ingle JN, Krook JE, Green SJ, Kukista TP, Everson LK, Ahman DL, Chang MN, Bisel HF, Windschitl HE, Twito DI, Pfeiffe MM 1986 Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4:4178
24. Early Breast Cancer Trialists’ Collaborative Group 1988 Effect of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N Engl J Med 319:1681
25. Jordan VC, Dix CJ, Naylor KE, Prestwich G, Rowsby L 1978 Nonsteroidal antiestrogens: their biological effects and potential mechanisms of action. J Toxicol Environ Health 4:364
26. Katzenellenbogen BS, Bhakoo HS, Ferguson ER, Lan NC, Tatee T, Tsai TLS, Katzenellenbogen JA 1979 Estrogen and antiestrogen action in reproductive tissues and tumors. Recent Prog Horm Res 35:259
27. Sutherland RL, Jordan VC (eds) 1981 Nonsteroidal antioestro-gens: molecular pharmacology and antitumour actions. Academic Press, Sydney, Australia
28. Sutherland RL, Murphy LC 1982 Mechanisms of oestrogen antagonism by nonsteroidal antioestrogens. Mol Cell Endocrinol 25:5
29. Furr BJA, Jordan VC 1984 The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127
30. Jordan VC 1984 Biochemical pharmacology of antiestrogen action. Pharmacol Rev 36:245
31. Jordan VC (ed) 1986 Estrogen/Antiestrogen action and breast cancer therapy. University of Wisconsin Press, Madison
32. Pasqualini JR, Sumida C, Glambiagi N 1988 Pharmacodynamic and biological effects of anti-estrogens in different models. J Steroid Biochem 31:613
33. Legha SS Tamoxifen in the treatment of breast cancer. Ann Intern Med 109:219
34. Buckley MMT, Goa KL 1989 Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 37:451
35. Lieberman ME, Maurer RA, Gorski J 1978 Estrogen control of prolactin synthesis in vitro. Proc Natl Acad Sci USA 75:5946
36. Lieberman ME, Jordan VC, Fritsch M, Santos MA, Gorski J 1983 Direct and reversible inhibition of estradiol-stimulated prolactin synthesis by antiestrogens in vitro. J Biol Chem 258:4734
37. Lieberman ME, Gorski J, Jordan VC 1983 An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro. J Biol Chem 258:4741
38. Jordan VC, Lieberman ME, Cormier EM, Koch R, Bagley J, Ruenitz P 1984 Structural requirements f
39. Jordan VC, Lieberman ME 1984 Estrogen-stimulated prolactin synthesis in vitro: Classification of agonist, partial agonist and antagonist actions based on structure. Mol Pharmacol 26:279
40. Jordan VC, Koch R, Mittal S, Schneider MR 1986 Oestrogenic and antioestrogenic actions in a series of triphenylbut-l-enes: modulation of prolactin synthesis in vitro. Br J Pharmacol 87:217
41. Robinson SP, Koch R, Jordan VC 1988 Estrogenic actions in vitro of hydroxylated derivatives of D16726 (Zindoxifene) an agent with known antimammary cancer activity in vivo. Cancer Res 48:784
42. Jordan VC, Koch R, Langan S, McCague R 1988 Ligand interaction at the estrogen receptor to program antiestrogen action: a study with non-steroidal compounds in vitro. Endocrinology 122:1449
43. Jordan VC, Koch R 1989 Regulation of prolactin synthesis in vitro by estrogenic and antiestrogenic derivatives of estradiol and estrone. Endocrinology 124:77
44. Jordan VC 1987 Laboratory models of breast cancer to aid the elucidation of antiestrogen action. J Lab Clin Med 109:267
45. Welsch CW 1985 Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Brenton Huggins. Cancer Res 45:3415
46. Engel LW, Young WA 1978 Human breast carcinoma cells in continuous culture: a review. Cancer Res 38:4339
47. Keydar I, Chen L, Karby S, Weiss FR, Delarea, Radu M, Chaitcik S, Brenner HJ 1979 Establishment and characterization of a cell line of human breast carcinoma origin. Eur J Cancer 15:659
48. Lippman ME, Monaco ME, Bolan G 1977 Effects of estrone, estradiol and estriol on hormone responsive breast cancer in long term tissue culture. Cancer Res 37:1901
49. Allegra JC, Lippman ME 1980 The effect of 17β estradiol and tamoxifen on the ZR-75-1 human breast cancer cell line in defined medium. Eur J Cancer Clin Oncol 16:1007
50. Shafie SM 1980 Estrogen and the growth of breast cancer: new evidence suggests indirect action. Science 209:701
51. Lippman ME, Bolan G 1975 Oestrogen-responsive human breast cancer in long term tissue culture. Nature 256:592
52. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS 1986 Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA 83:2496
53. Jordan VC 1988 The control of hormone-dependent breast cancer growth—are we talking about estrogen alone? Eur J Cancer Clin Oncol 24:1245
54. Welshons WV, Wolf ME, Murphy CS, Jordan VC 1988 Estrogenic activity of phenol red. Mol Cell Endocrinol 57:169
55. Bindal RD, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA 1988 Lipophyllic impurities, not phenolsulfophthalein, account for the estrogenic activity in commercial preparations of phenol red. J Steroid Biochem 31:287
56. Dodds EC, Lawson W 1936 Synthetic oestrogenic agents without the phenanthrene nucleus. Nature 137:996
57. Bindall RD, Katzenellenbogen JA 1988 Bis (4-hydroxyphenyl)2-phenoxysulphenyl)phenylmethane: isolation and structure elucidation of a novel estrogen from commercial preparations of phenol red (phenolsulfophthalein). J Med Chem 31:1978
58. Dodds EC, Lawson W 1937 A simple aromatic oestrogenic agent with an activity of the same order as that of oestrone. Nature 139:627
59. Zondek B, Bergmann M 1938 Phenol methyl ethers as oestrogenic agents. Biochem J 32:641
60. Dodds EC, Lawson W 1937 Oestrogenic activity of p-hydroxy-propenyl benzene (Anol). Nature 139:1068
61. Campbell NR, Dodds EC, Lawson W 1938 Oestrogenic activity of dianol, a dimeride of p-propenyl-phenol. Nature 141:78
62. Campbell NR, Dodds EC, Lawson W 1938 Oestrogenic activity of anol: a highly active phenol isolated from the byproducts. Nature 142:1121
63. Dodds EC, Golberg L, Lawson W, Robinson R 1938 Oestrogenic activity of certain synthetic compounds. Nature 141:247
64. Dodds EC, Lawson W, Noble RL 1938 Biological effects of the synthetic oestrogenic substance 4:4’-dihydroxy-a:β diethylstil-bene. Lancet 1:1389
65. Jordan VC, Collins MM, Rowsby L, Prestwich G 1977 A mono-hydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75:305
66. Jordan VC, Gosden B 1982 Importance of the alkylaminoethyoxy side chain for the estrogenic and antiestrogenic actions of tamoxifen and trioxifene in the immature rat uterus. Mol Cell Endocrinol 27:291
67. Lednicer D, Babcock JC, Marlatt PE, Lyster SC, Duncan DW 1965 Mammalian antifertility agents 1. Derivatives of 2,3 diphen-ylindenes. J Med Chem 8:52
68. Robertson DW, Katzenellenbogen JA, Hayes JR, Katzenellenbogen BS 1982 Antiestrogen basicity-activity relationships: a comparison of the estrogen receptor binding and anti-uterotrophic potencies of several analogues of (Z)-l,2 diphenyl-l-[4-[2-(di-methylamino)ethoxy]phenyl]-l-butene (tamoxifen, Nolvadex) having altered basicity. J Med Chem 25:167
69. Jarman M, Leung O-T, LeClercq G, Devleeschouwer N, Stoessel S, Coombes RC, Skilton RA 1986 Analogues of tamoxifen: the role of the basic side chain. Application of a whole cell oestrogen-receptor binding assay to N-oxides and quaternery salts. AntiCancer Drug Design 1:259
70. Murphy CS, Jordan VC 1989 Structural components necessary for the antiestrogenic activity of tamoxifen. J Steroid Biochem 34:407
71. Harper MJK, Walpole AL 1966 Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethy-lenes. Nature 212:87
72. Jordan VC, Haldeman B, Allen KE 1981 Geometric isomers of substituted triphenylethylenes and antiestrogen action. Endocrinology 108:1353
73. Katzenellenbogen BS, Norman MJ, Eckert RL, Peltz SW, Mangel WF 1984 Bioactivities, estrogen receptor interactions and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res 44:112
74. Katzenellenbogen JA, Carlson KE, Katzenellenbogen BS 1985 Facile geometric isomerization of phenolic nonsteroidal estrogens and antiestrogens: limitations to the interpretation of experiments characterizing the activity of individual isomers. J Steroid Biochem 22:589
75. Mittal S, Durani S, Kapil RS 1985 Structure-activity relationships of estrogens: receptor affinity and estrogen antagonist activity of certain (E)-and (Z)-l,2,3-triaryl-2-propen-l-ones. J Med Chem 28:492
76. Bignon E, Pons M, Gilbert J, Crastes de Paulet A 1988 Analogies and differences in the modulation of progesterone receptor induction and cell proliferation by estrogens and antiestrogens in MCF-7 human breast cancer cells: study with 24 triphenylacrylonitrile derivatives. J Steroid Chem 26:877
77. McCague R, Kuroda R, LeClercq G, Stoessel S 1986 Synthesis and estrogen receptor binding of 6,7-dihydro-8-phenyl-9-[4-[2-(dimethylamino)ethoxy]phenyl] 5H-benzocyclo-heptene, a non-isomerizabile analogue of tamoxifen. X-ray crystallographic studies. J Med Chem 29:2053
78. McCague R, LeClercq G, Jordan VC 1988 Non-isomerizable analogues of (Z)-and (E)-4 hydroxytamoxifen. Synthesis and endocrinological properties of substituted diphenylbenzocyclohep-tenes. J Med Chem 31:1285
79. McCague R, Jarman M, Leung OT, Foster AB, LeClercq G, Stoessel S 1988 Non-isomerizable antiestrogens related to tamoxifen. J Steroid Biochem 31:545
80. Murphy CS, Langan-Fahey S, McCague R, Jordan VC 1990 Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro. Mol Pharmacol, in press
81. Bignon E, Pons M, Crastes de Paulet A, Dare JC, Gilbert J, Abecassis J, Miguel JF, Ojasoo T, Raynaud JP 1989 Effect of triphenyl-acrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth. J Med Chem 32:2092
82. Acton D, Hill G, Tait BS 1983 Tricyclic triarylethylene antiestrogens: dibenz[b,f] oxepins, dibenzo[b,f] thiepins, dibenzo[a,e] cyclo octenes and dibenzo[b,f] thiocins. J Med Chem 26:1131
83. Jones CD, Suarez T, Massey EH, Black LJ, Tinsley FC 1979 Synthesis and antiestrogenic activity of [3,4-dihydro-2-(4-meth-oxyphenyl)-l-naphthalenyl] [4-[2-(l-pyrrolidinyl)ethoxy]-phenyl]methanone, methanesulfane acid salt. J Med Chem 22:962
84. Rose DP, Fisher AH, Jordan VC 1981 Activity of the antioestrogen trioxifene against AT-nitrosomethylurea-induced rat mammary carcinomas. Eur J Cancer Clin Oncol 17:893
85. Witte RS, Pruitt B, Tormey DC, Moss S, Rose DP, Falkson G, Carbone PP, Ramirez G, Falkson H, Pretorius FJ 1986 A phase I/II investigation of trioxifene mesylate in advanced breast cancer. Cancer 57:34
86. Lee RW, Rubdar AU, Blumenschein GR, Hortobagyi GN 1986 Trioxifene mesylate in the treatment of advanced breast cancer. Cancer 57:40
87. Black LJ, Jones CD, Falcone JF 1983 Antagonism of estrogen action with a new benzothiopene-derived antiestrogen. Life Sei 32:1031
88. Jones CD, Jevnikor MG, Pike AJ, Peters MK, Black LJ, Thompson AR, Falcone JF, Clemens JA 1984 Antiestrogens 2 structure-activity studies in a series of 3-aroyl-2-(4-hydroxy phenyl) benzo[b]thien-3-yl] [4-[2-(l-piperidinyl)ethoxy] phenyl] meth-anone hydrochloride (LY 156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J Med Chem 27:1057
89. Simard J, Labrie F 1985 Keoxifene shows pure antiestrogenic activity in pituitary gonadotrophs. Mol Cell Endocrinol 39:141
90. Clemens JA, Bennet DR, Black LJ, Jones CD 1983 Effects of a new antiestrogen, keoxifene (LY 156758) on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sei 32:2869
91. Gottardis MM, Jordan VC 1987 Antitumor actions of keoxifene and tamoxifen in the AT-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 47:4020
92. Gallick NG, Lindstrom TD 1983 Disposition and metabolism of a new antiestrogen LY156758 in rats, dogs and monkeys. Fed Proc 42:376
93. Hartman RW, Buchborn H, Kranzfelder G, Schönenberger H 1984 Ring substituted 1,2 dialkyated 1,2-bis (hydroxyphenyl) ethanes 2. Synthesis and estrogen receptor binding affinity of 4,4,-5 5’-and 6,6-disubstituted metahexestrols. J Med Chem 27:577
94. Hartmann RW, Kranzfelder G, von Angerer E, Schönenberger H 1980 Antiestrogens. Synthesis and evaluation of mammary tumor inhibiting activity of l,l,2,2-tetralkyl-l,2 diphenylethanes. J Med Chem 23:841
95. Hartman RW, Sinchai T, Krenzfelder G 1985 Antiproliferative effects of 1,2-diphenylethane oestrogens and antioestrogens on human breast cancer cells. J Cancer Res Clin Oncol 110:17
96. Hartman RW, Schwarz W, Heindl A, Schönenberger H 1985 Ring-substituted 1,1,2,2-tetra alkylated 1,2-bis (hydroxy phenyl) ethanes 4. Synthesis, estrogen receptor binding affinity and evaluation of antiestrogenic and mammary tumor inhibiting activity of symmetrically disubstituted l,l,2,2-tetramethyl-l,2-bis (hydroxy phenyl) ethanes. J Med Chem 28:1295
97. Hartman RW 1986 Influence of alkyl chain ramification on estradiol receptor binding affinity and intrinsic activity of 1,2-dialky-lated 1,2-bis (4-or 3-hydroxyphenyl) ethane estrogens and antiestrogens. J Med Chem 29:1668
98. Schneider MR 1986 Acetoxy substituted 1,1,2-triphenylbut-l-enes: estrogenic, antiestrogenic and mammary tumor inhibiting activity. J Cancer Res Clin Oncol 112:119
99. Schneider MR, Ball H, Schiller CD 1986 Catechol estrogens of the 1,1,2-triphenylbut-l-ene type: relationship between structure, estrogen receptor affinity, estrogenic and antiestrogenic properties and mammary tumor inhibiting activities. J Med Chem 29:1355
100. Schneider MR 1986 2-Alkyl substituted 1,1-bis (4-acetoxyphenyl)-2-phenylethenes. Estrogen receptor affinity, estrogenic and antiestrogenic properties and mammary tumor inhibiting activity. J Med Chem 29:1494
101. Schneider MR, Ball H 1986 2-phenylindenes: development of a new mammary tumor inhibiting antiestrogen by combination of estrogenic side effect lowering structural elements. J Med Chem 29:75
102. Von Angerer E 1984 Development of new drugs for endocrine tumour chemotherapy. Cancer Treat Rev II [Suppl] A: 147
103. Von Angerer E, Prekajoe J, Berger M 1985 The inhibitory effect of 5-acetoxy-2-(4-acetoxyphenyl)-l-ethyl-3-methylindole (D16726) on estrogen-dependent mammary tumors. Eur J Cancer Clin Oncol 21:531
104. Von Angerer E, Strohmeier J 1987 2-phenylindoles. Effect of N-benzylation on estrogen receptor affinity, estrogenic properties and mammary tumor inhibiting activity. J Med Chem 30:131
105. Schneider MR, Von Angerer E, Höhn W, Sinowatz F 1987 Antitumor activity of antiestrogenic phenylindoles on experimental prostate tumors. Eur J Cancer Clin Oncol 23:1005
106. Hilgard P, Stekar J, Wuttke W, Eiliger M, Holtei W 1988 Comparative pharmacology of Zindoxifene and tamoxifen. In: Bresciani F, King RJB, Lippman ME, Raynaud JP (eds) Progress in Cancer Research and Therapy, vol 35: Hormones and Cancer 3. New York, Raven Press, p 369
107. Stein RC, Dowsett M, Cunningham DC, Davenport J, Ford HT, Gazet J-C, Von Angerer E, Coombes RC 1990 Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study. Br J Cancer 61:431
108. Birnbock H, Ringshandl R, Von Angerer E 1987 Chromatographic analysis of the new antiestrogen zindoxifene and its metabolites in biological material. J Chromatogr 414:235
109. Kallio S, Kangas L, Blanco G, Johansson R, Kaijalainen M, Perila M, Pippo I, Sundquist H, Sodervall M, Toivola T 1986 A new triphenylethylene compound, Fc-1157a I. Hormonal effects. Cancer Chemother Pharmacol 17:103
110. Kangas L, Nieminen AL, Blaco G, Grontroos M, Kallico S, Karjalianen M, Perila M, Sondervall M, Toivola T 1986 A new triphenylethylene compound Fc-1157a II. Antitumor effects. Cancer Chemother Pharmacol 17:109
111. Robinson SP, Mauel DA, Jordan VC 1988 Antitumor actions of toremifene in the 7,12 dimethylbenzanthracene (DMBA)-induced rat mammary tumor model. Eur J Cancer Clin Oncol 24:1817
112. 3H-labeIed compounds in rat tumors. Nucl Med Biol 15:577
113. Vuorio T, Warri A, Sandberg M, Alitalo K, Vuorio E 1988 Expression of the C-Ha-ras and neu oncogenes in DMBA-induced antiestrogen treated rat mammary tumors. Int J Cancer 42:774
114. uC-toremifene in rats bearing DMBA-induced mammary carcinoma. Pharmacol Toxicol 64:373
115. Robinson SP, Jordan VC 1989 Antiestrogenic action of toremifene on hormone-dependent,-independent and heterogeneous breast tumor growth in the athymic mouse. Cancer Res 49:1758
116. Robinson SP, Goldstein D, Witt PL, Borden EC, Jordan VC 1990 Inhibition of hormone-dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon a2. Breast Cancer Res Treat 15:95
117. Simberg NH, Murai JT, Siiteri PK 1990 In vitro and in vivo binding of toremifene and its metabolites in rat uterus. J Steroid Biochem 36:197
118. Sipila H, Kangas L, Vuorilehto L, Kalapudas A, Eloranta M, Sondervall M, Toivola R, Antila M 1990 Metabolism of toremifene in the rat. J Steroid Biochem 36:211
119. Holleran WM, Gharbo SA, DeGregorio MW 1987 Quantitation of toremifene and its major metabolites in human plasma by highperformance liquid chromatography following fluorescent activation. Anal Letters 20:871
120. DeGregorio MW, Ford JM, Benz CC, Wiebe VJ 1989 Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance. J Clin Oncol 7:1359
121. Wiebe VJ, Benz CC, Shemano I, Cadman TB, DeGregario MW 1990 Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. Cancer Chemother Pharmacol 25:247
122. Sipila H, Nanto V, Kangas L, Antilla M, Halme T 1988 Binding of toremifene to human serum proteins. Pharmacol Toxicol 63:62
123. Robinson SP, Parker CJ, Jordan VC, Preclinical studies with toremifene as an antitumor agent. Breast Cancer Res Treat, in press
124. Watanabe N, Erie T, Koyama M 1989 Liquid chromatographic-atmospheric pressure ionizastion mass spectrometric analysis of toremifene metabolites in human urine. J Chromatog 497:169
125. DiSalle E, Zaccheo T, Ornati G 1990 Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat. J Steroid Biochem 36:203
126. Valavaara R, Pyrrhonen S, Heikkinen M, Rissanen P, Blanco G, Tholix E, Nordman E, Taskinen P, Holsti L, Hajba A 1988 Toremifene, a new antiestrogenic compound for treatment of advanced breast cancer. Phase II study. Eur J Cancer Clin Oncol 24:785
127. Ruenitz PC, Bagley JR, Molker CM 1983 Estrogenic and antiestrogenic activity of monophenolic analogs of tamoxifen (Z)-2-[P(l,2-diphenyl-l-butenyl-phenoxy]-N,7V dimethylethylamine. J Med Chem 25:1056
128. Roos W, Oeze L, Loser R, Eppenburger U 1983 Antiestrogenic action of 3-hydroxytamoxifen in the human breast cancer cell line MCF-7. J Natl Cancer Inst 71:55
129. Loser R, Siebel K, Roos W, Eppenburger U 1985 In vivo and in vitro antiestrogenic action of 3-hydroxy-tamoxifen, tamoxifen and 4-hydroxytamoxifen. Eur J Cancer Clin Oncol 21:985
130. Dietel M, Loser R, Rohlke P, Jonat W, Niendorf A, Gerding D, Kohr A, Holzel F, Arps H 1989 Effect of continuous vs. intermittent application of 3-hydroxytamoxifen or tamoxifen on the proliferation of the human breast cancer cell line MCF-7. J Cancer Res Clin Oncol 115:36
131. Wakeling AE, Bowler J 1988 Biology and mode of action of pure antiestrogens. J Steroid Biochem 30:141
132. Weatherill PJ, Wilson APM, Nicholson RI, Davis P, Wakeling AE 1988 Interaction of the antioestrogen ICI 164,384 with oestrogen receptors. J Steroid Biochem 30:263
133. Wakeling AE, Bowler J 1987 Steroidal pure antioestrogens. J Endocrinol 112:R7-R10
134. Wakeling AE, Bowler J 1988 Novel antioestrogens without partial agonist activity. J Steroid Biochem 31:645
135. Wakeling AE 1989 The potential for a novel pure antioestrogen. Horm Res 32 [Suppl 1]:257
136. Cormier EM, Jordan VC 1989 Contrasting ability of antiestrogens to inhibit MCF-7 growth stimulated by estradiol or epidermal growth factor. Eur J Cancer Clin Oncol 25:57
137. Thompson EW, Katz D, Shima TB, Wakeling AE, Lippman ME, Dickson RB 1989 ICI164,384 a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasion. Cancer Res 49:6929
138. Murphy CS, Meisner LF, Wu SQ, Jordan VC 1989 Short-and long-term estrogen deprivation of T47D human breast cancer cells in culture. Eur J Cancer Clin Oncol 25:1777
139. Pasqualini JR, Geliy C 1990 Biological response of the antiestrogen ICI-164,384 in human hormone-dependent and hormone-independent mammary cancer cell lines. Cancer Lett 50:133
140. Musgrove EA, Wakeling AE, Sutherland RL 1989 Points of action of estrogen antagonists and a calmodulin antagonist within the MCF-7 human breast cancer cell cycle. Cancer Res 49:2398
141. Reddel RR, Sutherland RL 1984 Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumour flare. Eur J Cancer Clin Oncol 20:1419
142. Gusberg SB 1990 Tamoxifen for breast cancer: associated endometrial cancer. Cancer 65:1463
143. Wakeling AE 1989 Comparative studies on the effect of steroidal and nonsteroidal oestrogen antagonists on the proliferation of human breast cancer cells. J Steroid Biochem 34:183
144. Nicholson RI, Gotting KE, Gee J, Walker KJ 1988 Action of oestrogens and antioestrogens on rat mammary gland development: relevance to breast cancer prevention. J Steroid Biochem 30:95
145. Gottardis MM, Jiang SY, Jeng MH, Jordan VC 1989 Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49:4090
146. Gottardis MM, Ricchio M, Satyaswaroop PG, Jordan VC 1990 Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa 101) in athymic mice. Cancer Res 50:3189
147. Clarke R, Brunner N, Katzenellenbogen BS, Thompson EW, Norman MJ, Koppi C, Paik S, Lippman ME, Dickson RB 1989 Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in viuo. Cancer Res 86:3469
148. Dickson RB, Lippman ME 1987 Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev 8:29
149. Dickson RB, McManaway ME, Lippman ME 1986 Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. Science 232:1540
150. H oncogene transfection on estrogen-independent tumorigenicity of estrogen-dependent human breast cancer cells. Cancer Res 47:5733
151. H DNA into MCF-7 human breast cancer cells bypasses dependence on estrogen for tumorigenicity. Science 228:725
152. DeLarco JE, Todero GJ 1978 Growth factors from murine sarcoma virus transformed cells. Proc Natl Acad Sci USA 75:4001
153. Anzano MS, Roberts AB, Smith JM, Sporn MB, DeLares JE 1983 Sarcoma growth factor from conditioned medium of virally transformed cells is composed of both type a and type transforming growth factors. Proc Natl Acad Sci USA 80:6264
154. Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, Roberts AB, Sporn MD, Goeddel DV 1985 Human transforming growth factor β complementary DNA sequence and expression in normal and transformed cells. Nature 316:701
155. Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF, Sporn MB 1985 Type /S transforming growth factor: bifunctional regulation of cellular growth. Proc Natl Acad Sci USA 82:119
156. Dijke PT, Hansen P, Iwata KK, Pieler C, Foulkes JG 1988 Identification of another member of the transforming growth factor type β gene family. Proc Natl Acad Sci USA 85:4715
157. Jakowlew SB, Dillard PJ, Kondaiah P, Sporn MB, Roberts AB Complementary deoxyribonucleic acid cloning of a novel transforming growth factor-β messenger ribonucleic acid from chick embryo chondrocytes. Mol Endocrinol 2:747
158. Jakowlew SB, Dillard PJ, Sporn MB, Roberts AB 1988 Complementary deoxyribonucleic acid cloning of a messenger ribonucleic acid from chick embryo chondrocytes. Mol Endocrinol 2:747
159. Madisen L, Webb NR, Rose TM, Marquardt I, Ikeda T, Twerdzik D, Seyedin S, Purchio AF 1988 Transforming growth factor-β2: cDNA cloning and sequencing analysis. DNA 7:1
160. Miller DA, Lee A, Peltor RH, Chen EY, Moses HL, Derynck R Murine transforming growth factor-β2 cDNA sequence and expression in adult tissue and embryos. Mol Endocrinol 3:1108
161. Kondaiah P, Sands MJ, Smith JM, Fields A, Roberts AB, Sporn MB, Melton DA 1990 Identification of a novel transforming growth factor-(TGF-/85) mRNA in Xenopus laevis. J Biol Chem 265:1089
162. Arteaga CL, Tandon AK, VonHoff DD, Osborne CK 1988 Transforming growth factor β: potential autocrine growth inhibitor of estrogen receptor negative human breast cells. Cancer Res 48:3898
163. Murphy LC, Dotzlaw H 1989 Regulation of transforming growth factor a and transforming growth factor /S messenger ribonucleic acid abundance in T47D human breast cancer cells. Mol Endocrinol 3:611
164. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynick R, Dickson RB 1987 Evidence that transforming growth factor β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48:417
165. Arrick BA, Korc M, Derynck R 1990 Differential regulation of expression of three transforming growth factor β species in human breast cancer cell lines by estradiol. Cancer Res 50:299
166. Zugmaier G, Ennis BW, Deschauer B, Katz D, Knabbe C, Wilding G, Daly P, Lippman ME, Dickson RB 1989 Transforming growth factors type β1 and β2 are equipotent growth inhibitors of human breast cancer cell lines. J Cell Physiol 141:353
167. Murphy CS, Pink JJ, Jordan VC, Characterization of a receptor-negative, hormone nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen free conditions. Cancer Res, in press
168. Rochefort H, Borgna JL 1981 Difference between oestrogen receptor activation by oestrogen and antioestrogen. Nature 292:257
169. 3H] estradiol binding by the antagonist clomiphene. J Biol Chem 257:11540
170. 3H]-4-hydroxytamoxifen. Evidence in support of contrasting receptor transitions mediated by different ligands. Biochemistry 24:8101
171. Pavlik EJ, van Nagell JR, Nelson K, Gallion H, Donaldson ES, Kenady DE, Baronowska-Kortylewicz J 1986 Antagonism to estradiol in the mouse: reduced entry of receptor complexes with 4-hydroxytamoxifen into a Mg++ soluble chromatin fraction. Endocrinology 118:1924
172. Faye JC, Fargin A, Bayard F 1986 Different interaction of estradiol and antiestrogens with the estrogen receptor of rat uterus. Mol Cell Endocrinology 47:119
173. Hansen JC, Gorski J 1986 Conformational transitions of the estrogen receptor monomer. Effect of estrogens, antiestrogen and temperature. J Biol Chem 261:13990
174. 3H] labeled antiestrogens and androstanediol in the uterus. Endocrinology 110:1355
175. Tate AC, Lieberman ME, Jordan VC 1984 The inhibition of prolactin synthesis in GH3 rat pituitary tumor cells by monohy-droxytamoxifen is associated with changes in the properties of the estrogen receptor. J Steroid Biochem 20:391
176. Tate AC, Greene GL, DeSombre ER, Jensen EV, Jordan VC 1984 Differences between estrogen and antiestrogen-estrogen receptor complexes from human breast tumors identified with an antibody raised against the estrogen receptor. Cancer Res 44:1012
177. Martin PM, Berthois Y, Jensen EV 1988 Binding of antiestrogens exposes an occult antigenic determinant in the human estrogen receptor. Proc Natl Acad Sci USA 85:2533
178. Eckert RL, Katzenellenbogen BS 1982 Physical properties of estrogen receptors complexes in MCF-7 human breast cancer cells. J Biol Chem 257:8840
179. 3H] tamoxifen aziridine. J Biol Chem 258:3487
180. Attardi B, Happe HK 1986 Comparison of the physicochemical properties of uterine nuclear estrogen receptors bound to estradiol or 4-hydroxytamoxifen. Endocrinology 119:904
181. Elliston JF, Katzenellenbogen BS 1988 Comparative analysis of estrogen receptors covalently labeled with an estrogen and an antiestrogen in several estrogen target cells as studied by limited proteolysis. J Steroid Biochem 29:559
182. Harlow KW, Smith DN, Katzenellenbogen JA, Green GL, Katzenellenbogen BS 1989 Identification of cystine-530 as the covalent attachment site of an affinity labeling estrogen (ketononestrola-ziridine) and antiestrogen (tamoxifenaziridine) on the human estrogen receptor. J Biol Chem 264:17476
183. Ratajczak T, Wilkinson SP, Brockway MJ, Hahnel R, Moritz RL, Begg GS, Simpson RJ 1989 The interaction site for tamoxifen aziridine with the bovine estrogen receptor. J Biol Chem 264:13453
184. 3H] desmethylnafoxidine aziridine. A comparison with the estrogen receptor complex. Mol Endocrinol 4:255
185. Simpson DM, Elliston JF, Katzenellenbogen JA 1987 Desmethylnafoxidine aziridine: an electrophilic affinity label for the estrogen receptor with high specificity and selectivity. J Steroid Biochem 28:233
186. Evans E, Baskevitch PP, Rochefort H 1982 Estrogen receptor DNA interaction. Differences between activation by estrogen and antiestrogen. Eur J Biochem 128:185
187. Singh RK, Ruh MF, Butler WB, Ruh TS 1986 Acceptor sites on chromatin for receptor bound by estrogen versus antiestrogen in antiestrogen-sensitive and-resistant MCF-7 cells. Endocrinology 118:1087
188. Metzer D, White JH, Chambon P 1988 The human oestrogen receptor functions in yeast. Nature 334:31
189. Webster NJCT, Green S, Jin SR, Chambon P 1988 The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell 54:199
190. Kumar V, Chambon P 1988 The estrogen receptor binds tightly to its response element as a ligand-induced homodimer. Cell 55:145
191. Curtis SW, Korach KS 1990 Uterine estrogen receptor interaction with estrogen responsive DNA sequence in utero: effect of ligand binding on receptor-DNA-complexes. Mol Endocrinol 4:276
192. Guiochon-Mantel A, Loosfelt H, Ragot T, Bailly A, Atger M, Misrahi M, Pericaudet M, Milgrom E 1988 Receptor bound to antiprogestin form abortive complexes with hormone responsive elements. Nature 336:695
193. Lees JA, Fawell SE, Parker MG 1989 Identification of two transactivation domains in the mouse oestrogen receptor. Nucleic Acids Res 17:5477
194. Fawell SE, White R, Howe S, Syndenham M, Page M, Parker MG 1990 Inhibition of estrogen receptor-DNA binding by the “pure” antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 87:6883
195. Jordan VC, Allen KE, Dix CJ 1980 The pharmacology of tamoxifen in laboratory animals. Cancer Treat Rep 64:745
196. Willis KJ, London DR, Wardtt WC, Butt WR, Lynch SS, Rudd BT 1977 Recurrent breast cancer treated with the antioestrogen tamoxifen: correlation between hormonal changes and clinical course. Br Med J i:425
197. Groom CV, Griffiths K 1976 Effect of the antioestrogen tamoxifen on plasma levels of luteinizing hormone, follicle stimulating hormone prolactin, oestradiol and progesterone in hormal premenopausal women. J Endocrinol 70:421
198. Shui RPC, Iwasiow BM 1985 Prolactin-inducible proteins in human breast cancer cells. J Biol Chem 260:11307
199. Biswas R, Vonderhaar BK 1987 Role of serum in the prolactin responsiveness of MCF-7 human breast cancer cells in long term tissue culture. Cancer Res 47:3509
200. Colletti RB, Roberts JD, Devlin JT, Copeland KC 1989 Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res 49:1882
201. Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ, Lippman ME, Rosen N 1989 Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol 3:509
202. Sakai F, Cheix F, Clavel M, Colon J, Mayer M, Ponnata E, Saez S 1978 Increases in steroid binding globulins induced by tamoxifen in patients with carcinoma of the breast. J Endocrinol 76:219
203. Szamel I, Vincze B, Hindy I, Herman I, Borvendog J, Eckhardt S 1986 Hormonal changes during a prolonged tamoxifen treatment in patients with advanced breast cancer. Oncology 43:7
204. Jordan VC, Fritz NF, Tormey DC 1987 Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III. Cancer Res 47:4517
205. Pommier RF, Woltering EA, Keenan ET, Fletcher WS 1987 The mechanism of hormone-sensitive breast cancer progression on antiestrogen therapy. Arch Surg 122:1311
206. Sutherland RL, Foo MS 1979 Differential binding of antiestrogens by rat uterine and chick oviduct cytosol. Biochem Biophys Res Commun 91:183
207. Sutherland RL, Murphy LC 1980 The binding of tamoxifen to human mammary carcinoma cytosol. Eur J Cancer Clin Oncol 16:1141
208. Sutherland RL, Murphy LC, Foo MS, Green MD, Whybourne AM, Krozowski ZS 1980 High affinity anti-oestrogen binding site distinct from the oestrogen receptor. Nature 288:273
209. Gulino A, Pasqualini JR 1982 Heterogeneity of binding sites for tamoxifen and tamoxifen derivatives in estrogen target and nontarget fetal organs of guinea pigs. Cancer Res 42:1913
210. Kon OL 1983 An antiestrogen binding protein in human tissues. J Biol Chem 258:3173
211. Miller MA, Katzenellenbogen BS 1983 Characterization and quantitation of antiestrogen binding sites in estrogen receptor-positive and-negative human breast cancer cell lines. Cancer Res 43:3094
212. Sudo K, Monsma FJ, Katzenellenbogen BS 1983 Antiestrogen-binding sites distinct from the estrogen receptor: subcellular localization, ligand specificity and distribution in tissues of the rat. Endocrinology 112:425
213. Watts CKW, Sutherland RL 1984 High affinity specific antiestrogen binding sites are concentrated in rough microsomal membranes of rat liver. Biochem Biophys Res Commun 120:109
214. Watts CKW, Sutherland RL 1986 Microsomal binding sites for antioestrogens in rat liver: properties and detergent solubilization. Biochem J 236:903
215. Watts CKW, Murphy LC, Sutherland RL 1984 Microsomal binding sites for nonsteroidal antiestrogens in MCF-7 human mammary carcinoma cells. Demonstration of high affinity and narrow specificity for basic ether derivatives of triphenylethylene. J Biol Chem 259:4223
216. Murphy LC, Sutherland RL 1983 Antitumor activity of clomi-phene analogs in vitro: relationship to affinity for the estrogen receptor and another high affinity antiestrogen-binding site. J Clin Endocrinol Metab 57:373
217. Ruenitz PC, Bagley JR 1985 Affinity of ligands other than triar-ylethylenes for liver microsomal antiestrogen binding sites. Biochem Pharmacol 34:2807
218. Lyman SD, Jordan VC 1985 Possible mechanisms for the agonist actions of tamoxifen and the antagonist actions of MER-25 (etha-moxytriphetol) in the mouse uterus. Biochem Pharmacol 34:2795
219. Watts CKW, Sutherland RL 1987 Studies on the ligand specificity and potential identity of microsomal antiestrogen-binding sites. Mol Pharmacol 31:541
220. Lam HYP 1984 Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Commun 118:27
221. Gulino A, Barrera G, Varea A, Farina A, Ferretti C, Screpanti I, Dianzoni MU, Frati L 1986 Calmodulin antagonism and growth-inhibiting activity of triphenylethylene antiestrogens in MCF-7 human breast cancer cells. Cancer Res 46:6274
222. Greenberg DA, Carpenter CL, Messing RO 1987 Calcium channel antagonist properties of the antineoplastic antiestrogen tamoxifen in the PC12 neurosecretory cell line. Cancer Res 47:70
223. Su HD, Mazzei GJ, Vogler WR, Kuo JF 1985 Effect of tamoxifen, a nonsteroidal antiestrogen, on phospholipid/calcium-dependent protein kinase and phosphorylation of its endogenous substrate proteins from the rat brain and ovary. Biochem Pharmacol 34:3649
224. O’Brian CA, Liskamp RM, Solomon DH, Weinstein IB 1985 Inhibition of protein kinase C by tamoxifen. Cancer Res 45:2462
225. O’Brian CA, Liskamp RM, Solomon DH, Weinstein IB 1986 Triphenylethylenes: a new class of protein kinase C inhibitor. J Natl Cancer Inst 76:1243
226. O’Brian CA, Housey GM, Weinstein IB 1988 Specific and direct binding of protein kinase C to an immobilized tamoxifen analogue. Cancer Res 48:3626
227. Ruenitz PC, Bagley JR, Pape CW 1984 Some chemical and biochemical aspects of liver microsomal metabolism of tamoxifen. Drug Metab Dispos 12:478
228. Ben-Baruch G, Schrieber G, Sokolovsky M 1982 Cooperativity patterns in the interaction of the antiestrogen drug clomiphene with the muscarinic receptors. Mol Pharmacol 21:287
229. Hiemke C, Ghraaf R 1984 Interaction of nonsteroidal antiestrogens with dopamine-receptor binding. J Steroid Biochem 21:663
230. Toney TW, Katzenellenbogen BS 1987 An evaluation of the interactions of antiestrogen with pituitary and striatal dopamine receptors. J Receptor Res 7:695
231. Brandes LJ, Macdonald LM, Bogdonovic RP 1985 Evidence that the antiestrogen binding site is a histamine or histamine-like receptor. Biochem Biophys Res Commun 126:905
232. Kroeger EA, Brandes LJ 1985 Evidence that tamoxifen is a histamine antagonist. Biochem Biophys Res Commun 131:750
233. Brandes LJ, Bogdonovic RP, Cawker MD, Bose R 1986 The antiproliferative properties of tamoxifen and phenothiazines may be mediated by a unique histamine receptor (?H3) distinct from the calmodulin-binding site. Cancer Chemother Pharmacol 18:21
234. Brandes LJ, Bogdonovic RP 1986 New evidence that the antiestrogen binding site is a novel growth promoting histamine receptor (?H3) which mediates the antiestrogenic and antiproliferative effects of tamoxifen. Biochem Biophys Res Commun 134:601
235. Sheen YY, Simpson DM, Katzenellenbogen BS 1985 An evaluation of the role of antiestrogen-binding sites in mediating the growth modulating effects of antiestrogens: studies using t-butyl-phenoxyethyl diethylamine, a compound lacking affinity for the estrogen receptor. Endocrinology 117:561
236. Brandes LJ, Hermonant MW 1984 A diphenylmethane derivative specific for the antiestrogen binding site found in rat liver micro-somes. Biochem Biophys Res Commun 123:724
237. Brandes LJ 1984 A diphenylmethane derivative selective for the antiestrogen binding site may help define its biological role. Biochem Biophys Res Commun 124:244
238. Fargin A, Bayard F, Faye JC, Traore M, Poirot M, Klaebe A, Perie JJ 1988 Further evidence for a biological role of antiestrogen binding sites in mediating the growth inhibitory action of diphenylmethane derivatives. Chem Biol Interact 66:101
239. Breckenridge WC, Lazier CB 1987 Tamoxifen-induced modification of serum lipoprotein phospholipids in the cockerel. Lipids 22:505
240. Clark JH, Winneker RC, Guthrie SC, Markaverich BM 1983 An endogenous ligand for the triphenylethylene antiestrogen binding site. Endocrinology 113:1167
241. Murphy PR, Butts C, Lazier CB 1984 Triphenylethylene antiestrogen binding sites in cockerel liver nuclei: evidence for an endogenous ligand. Endocrinology 15:420
242. Winneker RC, Guthrie SC, Clark JH 1983 Characterization of a triphenylethylene-antiestrogen binding site on rat serum low density lipoprotein. Endocrinology 112:1823
243. Murphy PR, Breckenridge WC, Lazier CB 1985 Binding of oxygenated cholesterol metabolites to antiestrogen binding sites from chicken liver. Biochem Biophys Res Commun 127:786
244. Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC, Metabolites, pharmacodynamics and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos, in press
245. Bloom ND, Fishman JH 1983 Tamoxifen treatment failures in hormonally responsive breast cancer. Cancer 51:1190
246. Jordan VC, Animal models of hormone dependent breast cancer. In: Harris JR, Heilman S, Henderson IC, Kinne DW (eds) Breast Diseases. JB Lippincott, Philadelphia, in press
247. Jordan VC 1976 Antiestrogenic and antitumor properties of tamoxifen in laboratory animals. Cancer Treat Rep 60:1409
248. Nicholson RI, Daniel P, Gaskell SJ, Syne JS, Davis P, Griffiths K 1979 The biochemistry of tamoxifen therapy of breast cancer. In: Agarwal MK (ed) Antihormones. Elsevier/North Holland, Amsterdam, pp 253-267
249. Matsuzawa A, Mizuno Y, Yamamoto T 1981 Antitumor effect of the antiestrogen tamoxifen on a pregnancy dependent mouse mammary tumor (TPDMT-4). Cancer Res 41:316
250. Sluyser M, Evers SG, DeGeoij CCJ 1981 Effect of monohydrox-ytamoxifen on mouse mammary tumors. Eur J Cancer Clin Oncol 17:1063
251. Rygaard J, Paulson CO 1969 Heterotransplantation of a human malignant tumor to “nude” mice. Acta Path Microbiol Suppl 77:758
252. Giovanella BC, Stehlin JS, Williams LJ 1974 Heterotransplantation of human malignant tumors in “nude” thymusless mice II. Malignant tumors induced by injection of cell cultures derived from human solid tumors. J Natl Cancer Inst 52:921
253. Giovanella BC, Stehlin JS, Williams LJ, Lee SS, Shepard RC 1978 Heterotransplantation of human cancers into nuce mice. Cancer 42:2269
254. Satyaswaroop PG, Zaino RJ, Mortel R 1983 Human endometrial adenocarcinoma transplanted into nude mice: growth regulation by estradiol. Science 219:58
255. Satyaswaroop PG, Zaino RJ, Mortel R 1984 Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 44:4006
256. Clark LL, Satyaswaroop PG 1985 Photoaffinity labeling of the progesterone receptor from human endometrial carcinoma. Cancer Res 45:5417
257. Soule HD, McGrath CM 1980 Estrogen proliferation of clonal human breast carcinoma cells in athymic mice. Cancer Lett 10:177
258. Shafie SM, Liotta LA 1980 Formation of metastasis by human breast carcinoma cells (MCF-7) in nude mice. Cancer Lett 11:81
259. Kubota T, Kubouchi K, Koh J, Enomoto K, Ishibiki K, Osahiko H 1983 Human breast carcinoma (MCF-7) serially transplanted into nude mice. Jap J Surg 13:381
260. Osborne CK, Rose CR, Coronado EB, Fugua SAW, Kitten LJ 1988 Secreted growth factors from estrogen receptor-negative human breast cancer do not support growth of estrogen receptor positive breast cancer in the nude mouse model. Breast Cancer Res Treat 11:211
261. Jordan VC, Gottardis MM, Robinson SP, Friedl A 1989 Immune-deficient animals to study “hormone-dependent” breast and endometrial cancer. J Steroid Biochem 34:169
262. Osborne CK, Hobbs K, Clark GM 1985 Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic mice. Cancer Res 45:584
263. Gottardis MM, Robinson SP, Jordan VC 1988 Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 30:311
264. Brunner N, Spang-Thomsen M, Vindel vL, Wolff J, Engleholm SA 1985 Effect of tamoxifen on the receptor positive T61 and the receptor negative T60 human breast carcinomas grown in nude mice. Eur J Cancer Clin Oncol 21:1349
265. Robinson SP, Jordan VC 1989 Antiestrogen action of toremifene on hormone-dependent,-independent and heterogeneous breast tumor growth in the athymic mouse. Cancer Res 49:1758
266. Terenius L 1970 Two modes of interaction between oestrogen and antioestrogen. Acta Endocrinol Suppl 64:47
267. Terenius L 1971 Structure-activity relationships of antiestrogens with regard to interaction with 17/3-oestradiol in the mouse uterus and vagina. Acta Endocrinol [Suppl] (Copenh) 66:431
268. Jordan VC, Rowsby L, Dix CJ, Prestwich G 1978 Dose-related effect of nonsteroidal antioestrogens and non-steroidal oestrogens on the measurement of cytoplasmic oestrogen receptors in the rat and mouse uterus. J Endocrinol 78:71
269. Gottardis MM, Jordan VC 1988 Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48:5183
270. Osborne CK, Coronado EB, Robinson JP 1987 Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 23:1189
271. Vaage J, Smith GH, Asch BB, Teramoto Y 1986 Mammary tumorigensis and tumor morphology in four C3H sublines with or without exogenous mammary tumor virus. Cancer Res 46:2096
272. Bittner JJ 1936 Some possible effects of nursing on the mammary gland tumor incidence in mice. Science 84:162
273. Bittner JJ 1937 Mammary tumors in mice in relation to nursing. Am J Cancer 30:530
274. Lathrop AE, Loeb L 1916 Further investigations on the origins of tumors in mice III on the part played by internal secretions in the spontaneous development of tumors. J Cancer Res 1:1
275. Lacassagne A 1932 Apperition de cancer de la mamelle chez le souris male, sourmise a des injection de folliculine. C R Acad Sci [D] (Paris) 195:630
276. Kalff M, Gross B, Beato M 1990 Progesterone receptor stimulates transcription of mouse mammary tumor virus in a cell free system. Nature 344:360
277. Matsuzawa A, Yamamoto T 1975 Response of a pregnancy-dependent mouse mammary tumor to hormones. J Natl Cancer Inst 55:447
278. Lee AE 1970 Mammary tumor development in BR6 mice: hormonal stimulation. Br J Cancer 24:568
279. Van Nie R, Thung PJ 1965 Responsiveness of mouse mammary tumors to pregnancy. Eur J Cancer 1:41
280. Shuyser M, Evers SG, Degeoij CCJ 1976 Sex hormone receptors in mammary tumors of GR mice. Nature 263:386
281. Jordan VC, Lababidi MK, Mirecki DM 1990 The antioestrogenic and antitumour properties of prolonged tamoxifen therapy in C3H/OUJ mice. Eur J Cancer 26:718
282. Jordan VC 1974 Antitumour activity of the antioestrogen ICI46.474 (tamoxifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model. J Steroid Biochem 5:354
283. Jordan VC 1976 Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 12:419
284. Tsai TLS, Katzenellenbogen BS 1977 Antagonism of development and growth of 7,12 dimethylbenz(a)anthracene-induced rat mammary tumors by the antiestrogen U23,469 and effects on estrogen and progesterone receptors. Cancer Res 37:1537
285. Turcot-Lemay L, Kelly PA 1980 Characterization of estradiol, progesterone and prolactin receptors in nitrosomethylurea-in-duced mammary tumors and effect of antiestrogen treatment on the development and growth of these tumors. Cancer Res 40:3232
286. Jordan VC, Allen KE 1980 Evaluation of the antitumour activity of the nonsteroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16:239
287. Wilson AJ, Tehrani F, Baum M 1982 Adjuvant tamoxifen therapy for early breast cancer: an experimental study with reference to oestrogen and progesterone receptors. Br J Surg 69:121
288. Jordan VC 1978 Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen treatment as a potential adjuvant therapy. Reviews on endocrine-related cancer, October Supplement 49-55, Macclesfield, ICI pharmaceuticals division
289. Jordan VC, Dix CJ, Allen KE 1979 The effectiveness of long-term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. In: Salmon SE, Jones SE (eds) Adjuvant Therapy of Cancer II. New York, Grune and Stratton, pp 19-26
290. Robinson SP, Jordan VC 1987 Reversal of the antitumor effects of tamoxifen by progesterone in the 7,12 dimethylbenzanthracene-induced rat mammary carcinoma model. Cancer Res 47:5386
291. Jordan VC 1988 Chemosuppression of breast cancer with tamoxifen: laboratory evidence and future clinical investigations. Cancer Invest 6:5-11
292. Jordan VC, Chemosuppression of breast cancer with long-term tamoxifen therapy. Preventive Medicine, in press
293. Cuzick J, Baum M 1985 Tamoxifen and contra-lateral breast cancer. Lancet 2:282
294. Fisher B, Constantino J, Redmond C, and the NSABP 1989 A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor positive tumors. N Engl J Med 32:479
295. Fornander T, Rutqvist LE, Cedermark BV, Glas U, Mattson A, Silversward JD, Skoog L, Somell A, Theve T, Wilking N, Asker-gren J, Hjolmar ML 1989 Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1:117
296. Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC) 1987 Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Lancet 2:171
297. Cummings FJ, Gray R, Davis TE, Tormey DC, Harris JE, Falkson G, Arsenau R 1985 Adjuvant tamoxifen treatment of elderly women with stage II breast cancer. Ann Intern Med 103:324
298. Ribeiro G, Palmer MK 1983 Adjuvant tamoxifen for operable carcinoma of the breast: report of a clinical trial by the Christie Hospital and Holt Radium Institute. Br Med J 286:827
299. Ribeiro G, Swindell R 1985 The Christie Hospital tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma—seven year results. Eur J Cancer Clin Oncol 21:897
300. Baum M, and the Nolvadex Adjuvant Trial Organization 1983 Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Lancet 1:257
301. Baum M, and the Nolvadex Adjuvant Trial Organization. 1985. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Lancet 1:836.
302. Baum M. and the Nolvadex Adjuvant Trial Organization. 1988. Controlled trial of tamoxifen as a single adjuvant agent in management of early breast cancer. Br J Cancer 57:608
303. Abram WP, Baum M, Berstock DA 1988 Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Preliminary analysis by the CRC adjuvant trial working party. Br J Cancer 57:604
304. Pritchard KI, Meakin JW, Boyd NF, Ambus K, DeBoer G, Dembo AJ, Paterson AHG, Sutherland DJA, Wilkinson RH, Bassett AA, Evans WK, Beale FA, Clark RM, Keane TJ 1984 A randomized trial of adjuvant tamoxifen in postmenopausal women with axillary node positive breast cancer. In: Adjuvant Therapy of Breast Cancer IV. Jones SE, Salmon SE (eds) Grune and Stratton, New York, pp 339-348
305. Ludwig Breast Cancer Group 1984 Randomized trial of chemoen-docrine therapy, endocrine therapy and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastases. Lancet 1:1256
306. Rose C, Thorpe SM, Andersen KW, Pedersen BV, Mouridsen HT, Blicher-Toft M, Rasmussen BB 1985 Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1:16
307. Rutqvist LE, Cedermark B, Glas U, Johansson H, Nordenskjold B, Skoog L, Sommell A, Theve T, Friberg S, Askergren J 1987 The Stockholm trial on adjuvant tamoxifen in early breast cancer. Breast Cancer Res Treat 10:255
308. Jordan VC 1983 Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications. Breast Cancer Res Treat 3 [Suppl 1]:73
309. Tormey DC 1987 Long-term adjuvant therapy with tamoxifen in breast cancer: how long is long? Ann Intern Med 106:762
310. Tormey DC, Jordan VC 1984 Long-term adjuvant tamoxifen therapy in node positive breast cancer: a metabolic and pilot clinical study. Breast Cancer Res Treat 4:297
311. Tormey DC, Rasmussen P, Jordan VC 1987 Update on long-term tamoxifen study (Letter to the Editor). Breast Cancer Res Treat 9:157
312. Jordan VC, Allen KE, Dix CJ 1980 The pharmacology of tamoxifen in laboratory animals. Cancer Treat Rep 64:745
313. Falkson HC, Gray R, Wolberg WH, Gilchrist KW, Harris JE, Tormey DC, Falkson G 1990 Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an ECOG Phase III study. J Clin Oncol 8:599
314. Fisher B and National Surgical Breast and Bowel Project Investigators 1987 Prolonging tamoxifen for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project Clinical Trial. Ann Intern Med 106:649
315. Fisher B, Redmond C, Brown A, Wolmark N, Wittliff JL, Fisher ER, Plotkin D, Sachs S, Wolter J, Frelich R, Desser R, Licalzi N, Geggi P, Campbell T, Elias EG, Prager D, Koontz P, Volk H, Dimitrov N, Gardner B, Lerner H, Shibata H and NSABP investigators 1981 Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 305:1
316. Fisher B, Redmond C, Brown A, Fisher ER, Wolmark N, Bowman D, Plotkin D, Wolter J, Bornstein R, Legault-Poisson S, Saffer EA and NSABP investigators 1986 Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5 year results from the National Surgical Adjuvant Breast and Bowel Project. J Clin Oncol 4:459
317. Fisher B, Redmond C, Brown A, Wickerham DL, Wolmark N, Allegra J, Escher G, Lippman ME, Savlov E, Wittliff JL, Fisher ER and NSABP investigators 1983 Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1:227
318. Delozier T, Julien JP, Juret P, Veyret C, Covette JE, Grai Y, Olliver JM, de Ranieri E 1986 Adjuvant tamoxifen in postmenopausal breast cancer: preliminary results of a randomized trial. Breast Cancer Res Treat 7:105
319. Fisher B, Redmond C, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham DL, Wolmark N, Margolese RG and other members of the NSABP 1990 Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8:1005
320. Dano K 1973 Active outward transport of daurorubicin in resistant Ehrlich ascites tumour cells. Biochim Biophys Acta 232:466
321. Inaba M, Koboyashi H, Sakwai Y, Johnson RK 1979 Active efflux of daunorubicin and Adriamycin® in sensitive and resistant sublines of P388 leukemia. Cancer Res 39:2220
322. Fojo A, Akiyama SI, Gottesman MM, Pastan 11985 Reduced drug accumulation in multiple drug resistant human KB carcinoma cell line. Cancer Res 45:3002
323. Riordan RJ, Deuchars K, Kartner W, Alan M, Trent J, Ling V 1985 Amplification of p-glycoprotein genes in multidrug resistant mammalian cell lines. Nature 316:817
324. Kartner N, Evernder-Parelle D, Bradley G, Ling V 1985 Detection of P-glycoprotein in multidrug resistant cell lines by monoclonal antibodies. Nature 316:820
325. Ramu A, Gläubiger A, Kuks Z 1984 Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and triparanol analogues. Cancer Res 44:4392
326. Kessel D 1986 Interaction among membrane transport systems: anthracyclines, calcium antagonists and anti-oestrogens. Biochem Pharmacol 35:2825
327. Chatterjee M, Harris AL 1990 Enhancement of Adriamycin® cytotoxicity in a multidrug resistant Chinese Hamster ovary (CHO) subline, CHO-Adr®, by toremifene and its modulation by alpha! acid glycoprotein. Eur J Cancer 26:432
328. Benz C, Cadman E, Gwin J 1983 Tamoxifen and 5-fluorouracil in breast cancer: cytotoxic synergism in vitro. Cancer Res 43:5298
329. Benz C, Santos G, Cadman E 1983 Tamoxifen and 5-fluorouracil in breast cancer: modulation of cellular RNA. Cancer Res 43:5304
330. Goldenberg GJ, Froese EK 1985 Antagonism of the cytocidal activity and uptake of melphalan by tamoxifen in human breast cancer cells in vitro. Biochem Pharmacol 34:763
331. Hug V, Hortobagyi GN, Drewinko B 1985 Tamoxifen citrate counteracts the antitumor effects of cytotoxic drugs in vitro. J Clin Oncol 3:1672
332. Osborne CK, Kitten L, Arteaga CL 1989 Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol 7:710
333. Nawata H, Chang MJ, Bronzert D, Lippman ME 1981 Estradiol independent growth of a subline of MCF-7 human breast cancer cells in culture. J Biol Chem 256:6895
334. Nawata H, Bronzert D, Lippman ME 1981 Isolation and characterization of a tamoxifen resistant line derived from MCF-7 human breast cancer cells. J Biol Chem 256:5016
335. Miller MA, Lippman ME, Katzenellengogen BS 1984 Antiestrogen binding in antiestrogen growth resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells. Cancer Res 44:5038
336. Faye JC, Jozan S, Redewilh G, Baulieu EE, Bayard F 1983 Physicochemical and genetic evidence for specific antiestrogen binding sites. Proc Natl Acad Sci USA 80:3158
337. Scholl SM, Huff KK, Lippman ME 1983 Antiestrogenic effects of LY117018 in MCF-7 cells. Endocrinology 113:611
338. Bronzert DA, Greene GL, Lippman ME 1985 Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY117018. Endocrinology 117:1409
339. Davidson NE, Bronzert DA, Chambon P, Gelman EP, Lippman ME 1986 Use of two MCF-7 variants to evaluate the growth regulating potential of estrogen-induced products. Cancer Res 46:1904
340. Rochefort H 1990 Cathepsin D in breast cancer. Breast Cancer Res Treat 16:3
341. 2 RNA and 52-and 160-kilodalton proteins in MCF-7 and two tamoxifen-resistant subline. J Biol Chem 259:10030
342. Johnson MD, Westley BR, May FEB 1989 Oestrogenic activity of tamoxifen and its metabolites on gene regulation and cell proliferation in MCF-7 breast cancer cells. Br J Cancer 59:727
343. Mullick A, Chambon P 1990 Characterization of the estrogen receptor in two antiestrogen-resistant cell lines LY2 and T47D. Cancer Res 50:333
344. van der Berg HW, Lynch M, Martin J, Nelson J, Dickson GR, Crockard AD 1989 Characterization of a tamoxifen-resistant variant of the ZR-75-1 human breast cancer cell line (ZR-75-9al) and stability of the resistant phenotype. Br J Cancer 59:522
345. Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y 1987 Proliferation, hormonal responsiveness and estrogen receptor content of MCF-7 human breast cancer cells grown in the shortterm and long-term absence of estrogens. Cancer Res 47:4355
346. Welshons WV, Jordan VC 1987 Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. Eur J Cancer Clin Oncol 23:1935
347. Clark R, Brunner N, Katzenellenbogen BS, Thompson EW, Norman MJ, Koppi C, Park S, Lippman ME, Dickson RB 1989 Progression of human breast cancer cells form hormone-dependent to hormone-independent growth both in vitro and in vivo. Proc Natl Acad Sci USA 86:3649
348. Friedl A, Gottardis MM, Pink J, Buchler DA, Jordan VC 1989 Enhanced growth of an estrogen receptor negative endometrial adenocarcinoma by estradiol in athymic mice. Cancer Res 49:4758
349. Glover JF, Irwin JT, Darbre PD 1988 Interaction of phenol red with estrogenic and antiestrogenic action on growth of human breast cancer cells ZR-75-1 and T47D. Cancer Res 48:3693
350. Westley BR, May FEB 1988 Oestrogen regulates oestrogen receptor mRNA levels in an oestrogen responsive human breast cancer cell line. Biochem Biophys Res Commun 155:1113
351. Koga M, Sutherland RL 1987 Epidermal growth factor partially reverses the growth inhibitory effects of antioestrogens on T47D human breast cancer cell growth. Biochem Biophys Res Commun 146:739
352. Koga M, Musgrove EA, Sutherland RL 1989 Modulation of the growth inhibitory effects of progestins and the antiestrogen hy-droxyclomiphene on human breast cancer cells by epidermal growth factor and insulin. Cancer Res 49:112
353. Robinson SP, Jordan VC 1989 The paracrine stimulation of MCF-7 cells by MDA-MB-231 cells: possible role in antiestrogen failure. Eur J Cancer Clin Oncol 25:493
354. Stoll BA 1977 Palliation by castration or by hormone administration. In: Breast Cancer Management Early and Late. Stoll BA (ed) W. Heinemann Medical Books, London, pp 133-146
355. Patterson JS, Settatree RS, Adam AK, Kemp JV 1980 Serum concentrations of tamoxifen and major metabolites during longterm Nolvadex therapy, correlated with clinical response. In Mouridsen HT, Palshoff T (eds) Breast Cancer—Experimental and Clinical Aspects, Pergamon Press, Oxford, pp 89-92
356. Jordan VC 1982 Metabolites of tamoxifen in animals and man: identification, pharmacology and significance. Breast Cancer Res Treat 2:123
357. Gottardis MM, Wagner RJ, Borden EC, Jordan VC 1989 Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Res 49:4765
358. Kemp JV, Adam HK, Wakeling AE, Slater R 1983 Identification and biological activity of tamoxifen metabolites in human serum. Biochem Pharmacol 32:2045
359. Jordan VC, Bain RR, Brown RR, Gosden B, Santos MA 1983 Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. Cancer Res 43:1446
360. Etienne MC, Milano G, Fischel JL, Frenay M, François E, For-mento JL, Gioanni J, Namer M 1989 Tamoxifen metabolism: pharmacokinetics and in vitro study. Br J Cancer 60:30
361. Lien EA, Solheim E, Kvinnsland S, Veland PM 1988 Identification of 4-hydroxy IV-desmethyltamoxifen as a metabolite in human bile. Cancer Res 48:2304
362. Lien EA, Solheim E, Lea OA, Lundgren S, Krinnsland S, Ueland PM 1989 Distribution of 4-hydroxy-IV-desmethyl tamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res 49:2175
363. Robinson SP, Langan-Fahey SM, Jordan VC 1989 Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts. Eur J Cancer Clin Oncol 25:1769
364. Fromson JM, Pearson S, Bramah S 1973 The metabolism of tamoxifen (ICI 46,474) Part I in laboratory animals. Xenobiotica 3:693
365. Murphy C, Fotsis T, Pantzar P, Aldercreutz H, Martin F 1987 Analysis of tamoxifen and its metabolites in human plasma by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM). J Steroid Biochem 26:547
366. Jordan VC, Robinson SP 1987 Species specific pharmacology of antiestrogens: role of metabolism. Fed Proc 46:1870
367. Lyman SD, Jordan VC 1985 Metabolism of tamoxifen and its uterotrophic activity. Biochem Pharmacol 34:2787
368. Mendehall DW, Kobayashi H, Shih FML, Sternson LA, Higuchi T, Fabian C 1978 Clinical analysis of tamoxifen, an antineoplastic agent, in plasma. Clin Chem 24:1518
369. Daniel CP, Gaskell SJ, Bishop H, Nicholson RI 1979 Determination of tamoxifen and an hydroxylated metabolite in plasma from patients with advanced breast cancer. J Endocrinol 83:401
370. Adam HK, Gay MA, Moore RH 1980 Measurement of tamoxifen in serum by thin layer densitometry. J Endocrinol 84:35
371. Camaggi CM, Strocchi E, Canova N 1983 High performance liquid chromatographic analysis of tamoxifen and major metabolites in human plasma. J Chromatogr 275:436
372. Wilbur BJ, Benz CC, DeGregorio MW 1985 Quantitation of tamoxifen, 4-hydroxytamoxifen and IV-desmethyltamoxifen in human plasma by high performance liquid chromatography. Anal Lett 18:1915
373. Milano G, Etienne MC, Khater R, Frenay M, Formento JL, Renee N, Moll JL, Francoval M, Berto M, Namer M 1987 Optimized analysis of tamoxifen and its main metabolite in the plasma and cytosol of mammary tumors. Br J Cancer 55:509
374. Nieder M, Jaeger H 1987 Quantitation of tamoxifen and IV-desmethyltamoxifen in human plasma by high-performance liquid chromatography, photochemical reaction and fluorescence detection and its application to biopharmaceutic investigations. J Chromatogr 413:207
375. Lein EA, Ueland PM, Solheim E, Kvinnsland S 1987 Determination of tamoxifen and four metabolites in serum by low-disper-sion liquid chromatography. Clin Chem 33:1608
376. Langan-Fahey SM, Tormey DC, Jordan VC, Tamoxifen metabolites in patients on long term adjuvant therapy for breast cancer. Eur J Cancer, in press
377. Brown RR, Bain RR, Jordan VC 1983 Determination of tamoxifen and metabolites in human serum by high performance liquid chromatography with post column fluorescence activation. J Chromatogr 272:351
378. Jordan VC 1989 Long-term adjuvant tamoxifen therapy. In: DeVita VT, Heilman S, Rosenberg SA (eds) Important Advances in Oncology, LB Lippincott, Philadelphia, pp 179-192
379. Jordan VC 1990 Long-term adjuvant tamoxifen therapy for breast cancer. Breast Cancer Res Treat 15:125
380. Senior BE, Cawood ML, Oakey RE, McKiddie M, Siddle DR 1978 A comparison of the effects of clomiphene and tamoxifen treatment on the concentration of oestradiol and progesterone in the peripheral plasma of infertile women. Clin Endocrinol 8:381
381. Sherman BM, Chapler FK, Crickard K, Wycoff D 1979 Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. J Clin Invest 64:398
382. Rose DP, Davis TE 1980 Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res 40:4043
383. Manni A, Pearson OH 1980 Antiestrogen-induced remission in premenopausal women with stage IV breast cancer: effects on ovarian function. Cancer Treat Rep 64:779
384. Tajima C, Fukushima T 1983 Endocrine profiles in tamoxifen-induced ovulatory cycles. Fertil Steril 40:23
385. Dnistrian AM, Greenberg EJ, Dillon HJ, Hakes TB, Fracchia AA, Schwartz MK 1985 Chemohormonal therapy and endocrine function in breast cancer patients. Cancer 56:63
386. Sawka CA, Pritchard KI, Paterson DJA, Thomsen DB, Shelley WE, Myers RE, Mobbs BG, Malkin A, Meakin JW 1986 Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast cancer. Cancer Res 46:3152
387. Jordan VC, Fritz NF, Tormey DC 1987 Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node positive patients with breast cancer. Cancer Res 47:624
388. Ravdin PM, Fritz NF, Tormey DC, Jordan VC 1988 Endocrine status of premenopausal node positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res 48:1026
389. Klopper A, Hall M 1971 New synthetic agent for the induction of ovulation: preliminary trial in women. Br Med J i:152
390. Williamson JG, Ellis JD 1973 The induction of ovulation by tamoxifen. J Obstet Gynaecol Br Comm 80:844
391. Bratherton DG, Brown CH, Buchanan R, Hall V, Kingsley P, Pillers EM, Wheeler TK, Williams CJ 1984 A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd vs. 20 mg bd. Br J Cancer 50:199
392. Nicholson RI, Walker KJ 1989 Use of LH-RH agonists in the treatment of breast disease. Proc R Soc Edinburgh [Biol Sci] 95b:271
393. Robertson JFR, Walker KJ, Nicholson RI, Blarney RW 1989 Combined endocrine effects of LH-RH agonist (Zoladex®) and tamoxifen (Nolvadex®) therapy in premenopausal women with breast cancer. Br J Surg 76:1262
394. Harper MJK, Walpole AL 1967 A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J Reprod Fertil 13:101
395. Harper MJK, Walpole AL 1967 Mode of action of ICI 46,474 in preventing implantation in rats. J Endocrinol 37:83
396. Labhsetwar AP 1970 Role of estrogen in ovulation. A study using the estrogen antagonist ICI 46,474. Endocrinology 87:542
397. Collins DJ, Hobbs JJ, Emmens CW 1971 Antiestrogenic and antifertility compounds 4:l,l,2-triarylalkan-l-ols and 1,1,2-triar-ylalk-l-enes containing basic ether group. J Med Chem 14:952
398. Longstaff S, Sigurdson H, O’Keefe M, Ogston S, Preece P 1989 A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinoma. Eur J Cancer Clin Oncol 25:1805
399. Kaiser-Kupfer ML, Lippman ME 1978 Tamoxifen retinopathy. Cancer Treat Rep 62:315
400. Turner RT, Wakley GK, Hannon KS, Bell NA 1987 Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J Bone Min Res 2:449
401. Jordan VC, Phelps E, Lingren JU 1987 Effect of antiestrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10:31
402. Turner RT, Wakley GK, Hannon KS, Bell NA 1988 Tamoxifen inhibits osteoclast mediated resorption of trabecular bone in ovarian hormone deficient rats. Endocrinology 122:1146
403. Wakley GK, Hannon KS, Bell NA, Turner RT 1988 The effects of tamoxifen on the osteopenia induced by sciatce neurotomy in the rat: a histomorphometric study. Calcif Tissue Int 43:883
404. Feldman S, Minne HW, Parvizi S, Pfeifer M, Lempert UG, Bauss F, Ziegler R 1989 Antiestrogen and antiandrogen administration reduce bone mass in the rat. Bone Mineral 7:245
405. Jordan VC, Dowse LJ 1976 Tamoxifen as an antitumour agent: effect on oestrogen binding. J Endocrinol 68:297
406. Jordan VC, Koerner S 1976 Tamoxifen as an antitumour agent: role of oestradiol and prolactin. J Endocrinol 68:305
407. Jordan VC, Jaspan T 1976 Tamoxifen as an antitumour agent: oestrogen binding as a predictive test for tumour response. J Endocrinol 68:453
408. Love RR, Mazess RB, Tormey DC, Barden HS, Newcomb PA, Jordan VC 1988 Bone mineral density in women with breast cancer treated for at least two years with tamoxifen. Breast Cancer Res Treat 12:297
409. Türken S, Siris E, Seldin E, Seldin D, Flaster E, Hyman G, Lindsay R 1989 Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 81:1086
410. Fentiman IS, Caleffi M, Rodin A 1989 Bone mineral content of women receiving tamoxifen for mastalgia. Br J Cancer 60:262
411. Powles TJ, Hardy JR, Ashley SE, Farrington GM, Cosgrove D, Davey JB, Dowsett M, McKinna JA, Nash AG, Sinnett HD, Tillyer CR, Treleven JG 1989 A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 60:126
412. Fornander T, Rutqvist LE, Sjöberg HE, Blomqvist L, Mattsson A, Glas U 1990 Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women. J Clin Oncol 8:1019
413. Rossner S, Wallgren A 1984 Serum lipoproteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 53:339
414. Brüning PF, Banfrer JMG, Hart AAM, de Jorg-Bakker M, Linders D, Van Loor J, Nooyen WJ 1988 Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer 58:497
415. Bertelli G, Pronzato P, Amoroso D, Cusimano MP, Conte PF, Montagma G, Bertolini S, Rosso R 1988 Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat 12:307
416. Caleffi M, Fentiman IS, Clark GM, Wang DY, Needham J, Clark K, LaVille A, Lewis B 1988 Effect of tamoxifen on oestrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast pain. J Endocrinol 119:335
417. Bagdade JD, Wolter J, Subbaiah PV, Ryan W 1990 Effect of tamoxifen treatment on plasma lipids and lipoproteins lipid composition. J Clin Endocrinol Metab 70:1132
418. Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP, DeMets DL 1990 Lipid and lipoprotein effects of tamoxifen therapy in postmenopausal patients with node negative breast cancer. JNCI 82:1327
419. Nevasaari K, Heikkimein M, Taskinen P 1978 Tamoxifen and thrombosis. Lancet 2:946
420. Hendrick A, Subraminian V 1980 Tamoxifen and thromboembolism. JAMA 243:514
421. Lipton A, Harvey HA, Hamilton RW 1984 Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep 68:887
422. Enck RE, Rios CN 1984 Tamoxifen treatment of metastatic breast cancer and antithrombin III levels. Cancer 53:2607
423. Fex G, Adielson G, Mattson W 1981 Oestrogen-like effects of tamoxifen on the concentration of proteins in plasma. Acta Endocrinol (Copenh) 97:109
424. Boccardo F, Buzzi L, Ruboyotti A, Nicolo G, Rosso R 1981 Oestrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology 38:281
425. Jordan VC 1975 Prolonged antioestrogen activity of ICI 46,474 in the ovariectomy mouse. J Reprod Fertil 52:251
426. Neven P, DeMuylder X, VanBelle Y, Vanderick G, DeMuylder E 1989 Tamoxifen and the uterus and endometrium. Lancet 1:375
427. Stewart HJ, Knight GM 1989 Tamoxifen and the uterus and endometrium. Lancet 1:375
428. Swenerton KD 1980 Treatment of advanced endometrial adenocarcinoma with tamoxifen. Cancer Treat Rep 64:805
429. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC 1988 Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48:812
430. Killackey MA, Hakes TB, Pierce VK 1985 Endometrial adenocarcinoma in breast cancer patients receiving tamoxifen. Cancer Treat Rep 69:237
431. Hardell L 1988 Pelvic irradiation and tamoxifen as risk factors for carcinoma of corpus uteri. Lancet 2:1432
432. Hardell L 1988 Tamoxifen as risk factor for carcinoma of corpus uteri. Lancet 2:563
433. Pike MC, Henderson BE, Krailo MD, Duke A, Roy S 1983 Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. Lancet 1:926
434. Bergkvist L, Adami H, Persson I, Hoover R, Schairer C 1989 The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 321:293
435. Longman SM, Buehring GC 1987 Oral contraceptives and breast cancer, in vitro effect of contraceptive steroids on human mammary cell growth. Cancer 59:281
436. Hissom JR, Moore MR 1987 Progestin effects on growth in the human breast cancer cell line T47D. Possible therapeutic implications. Biochem Biophys Res Commun 45:706
437. Mouridsen HT, Elleman K, Mattsson W 1979 Therapeutic effect of tamoxifen versus tamoxifen combined with medroxy progesterone acetate in advanced breast cancer in postmenopausal women. Cancer Treat Rep 63:171
438. Yager JD, Yager R 1980 Oral contraceptive steroids as promoters of hepatocarcinogenesis in female Sprague Dawley rats. Cancer Res 40:3680
439. Engstrom PF, Levin B, Moertel CG, Schutt A 1990 A phase II trial of tamoxifen in hepatocellular carcinoma. Cancer 65:2641
440. Cuzick J, Wang DY, Bulbrook RD 1986 The prevention of breast cancer. Lancet 1:83
441. Fentiman IS, Powles TJ 1987 Tamoxifen and benign breast problems. Lancet 2:1070
442. Love RR 1990 Prospect for antiestrogen chemoprevention of breast cancer. J Natl Cancer Inst 90:18
443. Lacassagne A 1936 Hormonal pathogenesis of adenocarcinoma of the breast. Am J Cancer 27:217
444. Lynch HT, Conway T, Fitzgibbon R, Schreiman J, Watson P, Marcus J, Fitzimmons ML, Lynch JF 1988 Age-of-onset heterogeneity in hereditary breast cancer—minimal clues for diagnosis. Breast Cancer Res Treat 12:275
445. Hillner BE, Hollenberg JP, Pauker SG 1986 Postmenopausal estrogens in prevention of osteoporosis. Am J Med 80:1115
446. Gotfredsen A, Nilas L, Riis BJ, Thomsen K, Christiansen C 1986 Bone changes occurring spontaneously and caused by oestrogen in early postmenopausal women: a local or genrealized phenomenon. Br Med J 292:1098
447. Hazzard WR 1989 Estrogen replacement and cardiovascular disease: serum lipids and blood pressure effects. Am J Obstet Gynecol 161:1847
448. Barrett-Connor E, Wingard DL, Criqui MH 1989 Postmenopausal estrogen use and heart disease risk factors in the 1980s. JAMA 261:2095
449. Lobo RA 1990 Cardiovascular implication of estrogen replacement therapy. Obstet Gynecol 75:185
450. Powles TJ, Hardy JR, Ashley SE, Cosgrove D, Davey JB, Dowsett M, McKinna A, Nash AG, Rindle SK, Sinnett HD, Tillyer CR, Treleven JG 1989 Chemoprevention of breast cancer. Breast Cancer Res Treat 14:23
451. Jordan VC 1990 Node negative breast cancer, tamoxifen and chemosuppression. J Natl Cancer Inst 82:1068
452. Jordan VC 1990 The forgotten group at risk for breast cancer. J Clin Oncol 8:1445
453. Jordan VC 1990 Prelude to breast cancer prevention with an antiestrogen. Annal Oncology 1:327